Conference Coverage

Olopatadine/mometasone combo is safe and effective

Publish date: March 14, 2018
Author(s):
Nick Andrews

 

REPORTING FROM AAAAI/WAO JOINT CONGRESS

ORLANDO – Twice-daily treatment with a combination of olopatadine and mometasone showed significant clinical benefit and demonstrated safety for patients with seasonal allergic rhinitis, according to the results of a phase 3 trial.

The combination, known as GSP301, is a fixed-dose nasal spray containing olopatadine, a Food and Drug Adminstration–approved antihistamine, and mometasone, an FDA-approved corticosteroid.

Dr. Frank Hampel of Central Texas Health Research in New Braunfels, Tex.

Dr. Frank Hampel

In a double-blind, parallel-group study, Frank Hampel, MD, of Central Texas Health Research in New Braunfels, Tex., and his colleagues randomized 1,180 patients who had seasonal allergic rhinitis and were aged 12 years or older to receive GSP301 (olopatadine 665 mcg/mometasone 25 mcg), olopatadine (665 mcg) alone, mometasone (25 mcg) alone, or placebo twice daily. They examined change from baseline in reflective total nasal symptom scores and compared the changes across treatment groups. The mean change in baseline scores was the primary endpoint.

The combination therapy demonstrated statistically significant improvement in scores, compared with those associated with placebo (P less than .001) and olopatadine alone (P = .003). It also showed benefit when compared with mometasone alone (P = .059), Dr. Hampel reported at the joint congress of the American Academy of Allergy, Asthma, and Immunology and the World Allergy Organization.

Pages

Next Article:

The ACA and Multiple Sclerosis